Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 10:59 PM
Ignite Modification Date: 2025-12-24 @ 10:59 PM
NCT ID: NCT05896969
Eligibility Criteria: Inclusion Criteria - 1. Male or female, ≥18 and ≤65 years of age, with BMI ≥18.5 and ≤35.0 kg/m2. 2. Participants must be either non smoking (no use of tobacco or nicotine products within 3 months prior to screening) or social smoker as defined by smoking no more than 5 cigarettes (or nicotine equivalent) a week and no smoking during screening period or on study. 3. Participants must be with elevated LDL-C defined as serum LDL levels between 2.6 - 4.9 mmol/L (inclusive) at screening. 4. Healthy (except for the LDL-C status) participants. 5. Participants must have fasting triglyceride level \<4.52 mmol/L (\<400mg/dL) at screening. 6. Sexually active females of childbearing potential and non-sterile males must be willing to use an acceptable contraceptive method throughout the study as detailed in section 8.1. 7. Able to understand the study procedures and provide signed informed consent to participate in the study. Exclusion Criteria - 1. Any clinically significant abnormal finding at physical examination in the opinion of the investigator. 2. Subjects with a history or presence of cardiovascular disease (including cerebrovascular accident (stroke or TIA) or disease, uncontrolled hypertension, familial hypercholesterolaemia, obstructive sleep apnoea, and peripheral artery), a diagnosis of diabetes mellitus given potential for hyperglycaemia defined as HbA1c greater or equal to 6.5%, or a non-alcoholic fatty liver disease. 3. Received Leqvio (inclisiran) treatment in less than 6 months ago. 4. Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 65 Years
Study: NCT05896969
Study Brief:
Protocol Section: NCT05896969